Ozempic, the popular diabetes and weight loss drug, has been a game-changer for millions, but its sky-high price has drawn criticism.
Now, Medicare is stepping in, potentially bringing relief to patients and taxpayers alike. Here’s what you need to know about this important development and how it could make Ozempic more affordable.
Why Is Ozempic So Expensive?
Ozempic, along with similar drugs like Wegovy, has seen explosive demand for its ability to manage Type 2 diabetes and help with weight loss. However, its price tag has left many Americans struggling to afford it and looking for ways to save money on healthcare costs.
Medicare Part D, which covers prescription drugs, spent billions on Ozempic last year. For many on fixed incomes, this has meant cutting pills in half or skipping doses entirely. The price controversy has fueled public outcry, with many calling for government intervention. It’s one of many reasons that the USA did not make our list of 30 countries with great healthcare systems.
Medicare’s Plan to Negotiate Drug Prices
Under the Inflation Reduction Act of 2022, Medicare has the authority to negotiate prices on certain high-cost drugs, and Ozempic is now on the list. This marks a major shift in how drug prices are determined in the U.S., as pharmaceutical companies have traditionally had free rein to set their prices. Medicare’s negotiations with drugmakers are expected to begin soon, with new prices taking effect in 2027.
While 2027 might feel far away, this is a critical first step. The stakes are high, as more than 5 million Medicare beneficiaries used Ozempic last year, and the drug accounted for a significant portion of the program’s $41 billion in spending on the newly selected drugs.
Related: Guilt-Free Alternatives to Junk Food Classics
How Medicare Could Make Ozempic Cheaper
If Medicare can strike a deal, it could save billions of dollars and lower out-of-pocket costs for seniors who rely on Ozempic. This would also open the door for Medicare to cover Ozempic for additional FDA-approved uses, such as reducing heart disease risk, further increasing its accessibility.
Drugmakers, however, are not thrilled. Novo Nordisk, Ozempic’s manufacturer, has publicly opposed the negotiations but agreed to work with Medicare to find solutions. If they refuse to negotiate, they could face hefty tax penalties or lose access to the massive Medicare market.
Related: 30 Healthy Snacks for Busy People
What This Means for Patients
For Medicare beneficiaries, cheaper Ozempic prices could be life-changing. Not only would it ease financial burdens, but it could also expand access to this groundbreaking medication. However, the process is far from over. Drugmakers are fighting back in court, and political uncertainty looms, especially with a potential shift in administration.
Still, this move by Medicare is a big deal. If successful, it could set a precedent for making other life-saving drugs more affordable, ensuring Americans no longer have to choose between their health and their wallets.